PLAUR and COVID-19: In a cohort of COVID-19 patients from India, originally recruited for a randomized control trial on convalescent plasma therapy, we found significantly high plasma levels of soluble uPAR in severe COVID-19 patients early in the course of severity, which correlated with an expanded myeloid cell compartment in circulation.